A case report and discussion of cetuximab-induced folliculitis

American Journal of Clinical Dermatology

Volumn 7, Issue 5, 2006, Pages 333-336

  Adams, Derrick H ^a,b   Nutt, Terri ^a  

^a DAVID GRANT MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; CLINDAMYCIN; IRINOTECAN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CASE REPORT; COLORECTAL CARCINOMA; FOLLICULITIS; HUMAN; INTESTINE RESECTION; LOTION; LUNG METASTASIS; MALE; PRIORITY JOURNAL; RASH; SKIN BIOPSY; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG ANTAGONISM; LUNG TUMOR; METASTASIS; PATHOLOGY; REMISSION;

AGED; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINDAMYCIN; COLORECTAL NEOPLASMS; FOLLICULITIS; HUMANS; LUNG NEOPLASMS; MALE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION INDUCTION;

EID: 34347244237     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200607050-00008     Document Type: Article

References (15)

1. Perez-Soler R, Delford JP. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10: 345-56
2. Erbitux® (cetuximab) prescribing information [package insert]. New York: Im-Clone Systems Inc, 2004
3. Monti M, Mancini L, Mancini L, et al. Complications of therapy and a diagnostic dilemma case: case 2. Cutaneous toxicity induced by cetuximab. J Clin Oncol 2003 Dec; 21 (24): 4651-3
4. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110-24
5. Kimyai-Asadi A, Ming H. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors: a case report. Arch Dermatol 2002 Jan; 138: 129-30
6. Kirn TF. Tx elusive for cancer drug rash. Skin & Allergy News 2005 Jan; 36 (1): 1-20
7. Hansen LA, Alexander N. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol 1997; 150: 1959-75
8. Busam KJ, Capodieci P, Motzer R. Cutaneous side-effects in cancer patients treated with antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-76
9. Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598-601
10. Boucher KW, Davidson K, Mirakhur B. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 2002; 47: 632-3
11. Walton L, Gibeau C, Lachapelle JM. Acneiform eruptions by cetuximab. Ann Dermatol Venereol 2003 Apr; 130 (4): 443-6
12. Shah N, Kris M, Pao W, et al. Practical management of patients with non-small cell lung cancer treated with gefitinib. J Clin Oncol 2005 Jan; 23 (1): 165-74
13. Liu WW, Innocenti F, Chen P. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003; 9: 1009-12
14. Micantonio T, Fargnoli M, Ricevuto E, et al. Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy. Arch Dermatol 2005 Sep; 141 (9): 1173-4
15. Gutzmer R, Werfel T, Mao R, et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005 Oct; 153 (4): 849-51